Moneycontrol PRO
biocon biologics
Jump to
12 Results Found
  • Biocon Biologics, Viatris receive EC nod for biosimilar Bevacizumab Apr 26, 2021 10:31 AM IST

    Biocon Biologics, Viatris receive EC nod for biosimilar Bevacizumab

    The nod came following the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency, it said.

  • Sovereign wealth fund ADQ to invest $75 million in Biocon Biologics, deal values firm at around $4 billion Jan 07, 2021 05:05 PM IST

    Sovereign wealth fund ADQ to invest $75 million in Biocon Biologics, deal values firm at around $4 billion

    The current investment has put the post-money valuation of Biocon Biologics at ~$4.17 billion, said Kiran Mazumdar-Shaw, Executive Chairperson of Biocon

  • IPO-bound Biocon Biologics in talks with Abu Dhabi fund ADQ to raise fresh capital Nov 24, 2020 12:21 PM IST

    IPO-bound Biocon Biologics in talks with Abu Dhabi fund ADQ to raise fresh capital

    If the negotiations fructify— coming two weeks after the Goldman Sachs deal—it would mark the fourth successive investment in the Kiran Mazumdar Shaw-led Biocon unit in 2020.The last fundraise was struck at a valuation of $3.94 billion.

  • Goldman Sachs to invest $150 million in Biocon's IPO-bound subsidiary Biocon Biologics Nov 07, 2020 04:04 PM IST

    Goldman Sachs to invest $150 million in Biocon's IPO-bound subsidiary Biocon Biologics

    As per the terms of the proposed agreement, Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion. The transaction is subject to customary approvals and conditions

  • Aim to list Biocon Biologics on capital markets by 2023: CFO MB Chinappa Aug 03, 2020 12:58 PM IST

    Aim to list Biocon Biologics on capital markets by 2023: CFO MB Chinappa

    Biocon Biologics has raised $105 million so far this calendar year through two primary equity infusions.

  • Tata Capital to invest Rs 225 crore in Biocon Biologics for minority stake Jul 31, 2020 12:25 PM IST

    Tata Capital to invest Rs 225 crore in Biocon Biologics for minority stake

    The deal for 0.85 percent stake values Biocon Biologics at an equity valuation of Rs 26,250 crore, or $3.5 billion

  • Biocon Biologics partners with Voluntis for digital therapeutics for diabetics patients Jul 21, 2020 11:30 AM IST

    Biocon Biologics partners with Voluntis for digital therapeutics for diabetics patients

    The licensing agreement between Malaysian subsidiary Biocon Sdn. Bhd. and Voluntis will allow Biocon Biologics to offer therapeutic product 'Insulia' to type 2 diabetes patients across several markets in the world, Biocon Biologics said in a statement.

  • Biocon Biologics' drug substance facilities in Bengaluru get EU GMP certification May 12, 2020 02:10 PM IST

    Biocon Biologics' drug substance facilities in Bengaluru get EU GMP certification

    Biocon on Tuesday said its arm Biocon Biologics has received EU Good Manufacturing Practice (GMP) certification for its biologics drug substance facilities in Bengaluru.

  • Biocon Biologics receives EIR from USFDA for 2 manufacturing facilities Apr 16, 2020 10:15 AM IST

    Biocon Biologics receives EIR from USFDA for 2 manufacturing facilities

    The inspection was conducted between September 10 and September 19, 2019, a company spokesperson said, adding, Biocon Biologics has responded to the regulator on the eight observations from this inspection, in October last year.

  • Reporter's Take | Why Biocon Biologics is valued at $3 bn? Jan 07, 2020 09:29 PM IST

    Reporter's Take | Why Biocon Biologics is valued at $3 bn?

    Moneycontrol’s Jerome Anthony talks to pharma correspondent Viswanath Pilla to find out why the company has received such a high valuation.

  • Biocon Biologics IPO: Syngene encore on the cards Jan 07, 2020 08:02 PM IST

    Biocon Biologics IPO: Syngene encore on the cards

    Syngene, which was listed in August 2015, raised Rs 550 crore. The IPO was subscribed 32 times. Incidentally, True North was an investor in Syngene before it was listed.

  • True North to acquire 2.44% stake in Biocon Biologics Jan 06, 2020 04:16 PM IST

    True North to acquire 2.44% stake in Biocon Biologics

    Biocon said it would use the proceeds of stake sale for expansion of R&D and manufacturing capabilities.

Sections
ISO 27001 - BSI Assurance Mark